# Agilent Technologies

**Source:** https://geo.sig.ai/brands/agilent-technologies  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** agilent.com  
**Last Updated:** 2026-04-14

## Summary

Santa Clara analytical instruments (NYSE: A) at $6.95B FY2025 revenue; Q4 +9.4% recovery from pharma destocking, LC-MS/gas chromatography leader for drug dev and food safety competing with Waters and Thermo Fisher.

## Company Overview

Agilent Technologies, Inc. is a Santa Clara, California-based life sciences, diagnostics, and applied chemical analysis instruments company — publicly traded on the New York Stock Exchange (NYSE: A) as an S&P 500 Health Care component — designing, manufacturing, and supporting analytical instruments, consumables, software, and services for pharmaceutical, biopharmaceutical, food safety, environmental, clinical, and academic laboratory applications through approximately 17,000 employees worldwide. In fiscal year 2025 (ending October 2025), Agilent reported full-year revenue of $6.95 billion, with Q4 FY2025 revenue of $1.86 billion (+9.4% reported, +7.2% core growth) — accelerating from the prior year's market correction when the pharmaceutical and biopharma industry destocked lab consumables following the COVID-era inventory surge. The Life Sciences and Diagnostics Markets Group delivered Q4 FY2025 revenue of $755 million (+15% reported, +11% core), reflecting a robust recovery in pharmaceutical R&D laboratory spending. Founded in 1999 as a spinoff from Hewlett-Packard's analytical instruments division (carrying forward HP's tradition of precision measurement instruments dating to 1939), Agilent is organized around three segments: Life Sciences & Applied Markets (liquid chromatography, mass spectrometry, gas chromatography systems for drug development and food/environmental testing), Diagnostics & Genomics (pathology reagents, next-generation sequencing, FISH probes for cancer diagnostics), and Agilent CrossLab (instrument services, calibration, laboratory informatics, and consumables replacement).

Agilent's analytical instrumentation model creates recurring revenue through the instrument-consumables-services flywheel: when a pharmaceutical company installs a $200,000 Agilent liquid chromatography-mass spectrometry (LC-MS) system for small molecule drug development, it creates 10-15 years of consumable purchases (LC columns, mobile phase chemicals, calibration standards at $20,000-50,000 annually per instrument) and service contract renewals ($25,000-40,000 annually per instrument) — generating 3-5x the original instrument purchase price in recurring revenue over the system's service life. The pharmaceutical industry's drug discovery and quality control workflows are calibrated to Agilent's specific instrument parameters, method validation libraries, and software platforms (OpenLab CDS), creating switching costs that make ripping out an installed Agilent LC-MS system in a GMP-regulated pharmaceutical lab economically comparable to revalidating every analytical method from scratch.

In 2025, Agilent competes in analytical instruments, laboratory informatics, and life science tools against Waters Corporation (NYSE: WAT, $3.0B revenue, LC-MS systems), Thermo Fisher Scientific (NYSE: TMO, $43B revenue, broad scientific instruments), and Bio-Rad Laboratories (NYSE: BIO, $2.8B revenue, life science research and diagnostics) for pharmaceutical R&D lab capital equipment spending and consumables volume. The FY2025 recovery (+9.4% Q4 growth) reflects the end of the pharma/biopharma destocking cycle — a correction that impacted all life science tools companies in 2023-2024 as customers depleted COVID-era inventory surpluses. The Diagnostics & Genomics segment's next-generation sequencing reagents and FISH probes serve the oncology diagnostic market, where companion diagnostic agreements with pharmaceutical companies (tying Agilent's genomic tests to specific cancer drug approvals) create regulatory moats. The 2025 strategy focuses on capital equipment upgrade cycle capture as pharma/biopharma labs replace aging instruments, expanding the Agilent CrossLab services annuity on the global installed base, and growing the cell biology and flow cytometry portfolio for next-generation drug development workflows.

## Frequently Asked Questions

### What does Agilent Technologies do?
Agilent Technologies is a global leader in analytical and clinical laboratory technologies, providing instruments, software, services, and consumables for life sciences, diagnostics, and applied chemical markets. The company's solutions include chromatography systems, mass spectrometry, genomics platforms, cell analysis, spectroscopy, and companion diagnostics. Agilent serves pharmaceutical, biotechnology, academic research, clinical diagnostics, environmental testing, food safety, and petrochemical laboratories worldwide with approximately 18,000 employees.

### Who are Agilent's customers and target markets?
Agilent serves analytical and clinical laboratories across multiple sectors: pharmaceutical companies developing new drugs, biotechnology firms advancing therapies, academic researchers conducting basic science, clinical diagnostic labs analyzing patient samples, environmental agencies testing water and soil, food safety labs ensuring product quality, and petrochemical companies analyzing materials. Key customer segments include biopharma R&D (pharmaceutical and biotechnology), clinical diagnostics, environmental and forensics, food safety, and chemical and energy industries.

### When was Agilent Technologies founded?
Agilent Technologies was officially established in May 1999 as a spin-off from Hewlett-Packard Company. HP announced the formation on March 2, 1999, and the company received its name on July 28, 1999. Agilent had its record-breaking IPO on November 18, 1999 (raising $2.1 billion), and became fully independent on June 2, 2000, when HP distributed Agilent shares to shareholders. Though founded in 1999, Agilent's heritage traces back to HP's founding in 1938.

### Where is Agilent Technologies headquartered?
Agilent Technologies is headquartered in Santa Clara, California, in the heart of Silicon Valley. The company operates globally with approximately 18,000 employees worldwide, maintaining significant operations in the United States, Europe, and Asia. Agilent has manufacturing, R&D, and service facilities in multiple countries to support its global customer base in life sciences and diagnostics markets.

### What is Agilent's financial performance?
Agilent reported fiscal year 2025 revenue of $6.95 billion, up from $6.51 billion in FY2024. Fourth quarter 2025 revenue was $1.86 billion, representing 9.4% reported growth and 7.2% core growth. The Life Sciences and Diagnostics Markets Group showed strong performance with Q4 2025 revenue of $755 million (15% growth). Net income in FY2024 was $1.29 billion. The company employs approximately 18,000 people worldwide and maintains a diversified revenue base across three business segments.

### What makes Agilent different from competitors?
Agilent differentiates itself through comprehensive end-to-end laboratory solutions spanning instruments, consumables, software, and services—the 'One Agilent' approach. Unlike competitors focused on single technology areas, Agilent offers integrated workflows across chromatography, mass spectrometry, genomics, and diagnostics. The company's CrossLab services provide ongoing support, consumables, and instrument maintenance, creating strong customer relationships. Agilent's heritage from HP provides deep engineering expertise, while strategic acquisitions (Varian, Dako, ACEA) have built leadership in key growth areas like cancer diagnostics.

### Who are Agilent's main competitors?
Agilent competes with Thermo Fisher Scientific (largest competitor across multiple segments), Waters Corporation and Shimadzu in chromatography, PerkinElmer in analytical instruments, Illumina and Thermo Fisher in genomics, Roche Diagnostics and Danaher (Beckman Coulter, Leica Biosystems) in pathology and diagnostics, and Bio-Rad Laboratories in life sciences research. The competitive landscape varies by product line, with Agilent maintaining leadership positions in liquid chromatography, mass spectrometry, and cancer companion diagnostics.

### How can I contact Agilent Technologies?
Agilent Technologies' headquarters is located in Santa Clara, California. The company can be reached through its official website at www.agilent.com, which provides product information, technical support, and customer service resources. For investor relations, visit investor.agilent.com. Agilent maintains global support centers with technical specialists available to assist customers with instrument operation, method development, and troubleshooting. Regional sales and service offices are located worldwide.

### Is Agilent Technologies hiring?
Yes, Agilent actively recruits talent across engineering, R&D, sales, service, manufacturing, and corporate functions. With approximately 18,000 employees worldwide and continued growth in life sciences and diagnostics markets, the company regularly posts opportunities for scientists, engineers, field service engineers, sales specialists, and support staff. Career opportunities can be found on the Agilent careers website. The company particularly seeks expertise in analytical chemistry, molecular biology, software development, and laboratory diagnostics.

### What's the latest news about Agilent?
Recent developments include Padraig McDonnell becoming CEO in May 2024; strong Q4 FY2025 results with $1.86 billion revenue (9.4% growth); strategic partnerships announced in 2025 with Abcam for IHC companion diagnostics, Ubix Therapeutics for cancer research, and Lunit for AI-powered diagnostics; European IVDR certification for MMR IHC Panel for colorectal cancer; expansion of Avida DNA Cancer Panels for liquid biopsy; launch of new Seahorse XF Flex Analyzer for organoid workflows; and My Green Lab Certification achievements at refurbishment centers scoring 90% and 87%.

### What is Agilent's market position in analytical instruments?
Agilent holds leadership positions in multiple segments: #1 in liquid chromatography (LC) globally, top-3 in gas chromatography (GC), leading position in mass spectrometry, and significant presence in genomics and cell analysis following strategic acquisitions. In the life sciences and diagnostics markets, Agilent's 49% revenue share in this segment ($3.22 billion in FY2024) demonstrates market leadership. The company is recognized as a premier provider of analytical instrumentation for pharmaceutical, biotechnology, and clinical diagnostics applications.

### What are Agilent's future plans and growth strategy?
Agilent's strategy focuses on accelerating growth in biopharma and clinical diagnostics through innovation in companion diagnostics, AI-powered solutions, and cell analysis platforms. The company is expanding partnerships with biopharma leaders (Abcam, Ubix, Lunit) to develop next-generation cancer diagnostics and therapeutics. Key growth drivers include IVDR-compliant pathology products for European markets, liquid biopsy solutions for early cancer detection, real-time metabolic analysis systems, and AI-enhanced diagnostic tools. Agilent targets continued market share gains in chromatography and mass spectrometry while building leadership in high-growth areas like precision medicine and organoid research.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*